David A. Kennard
Corporate Officer/Principal bij Royal Pharmaceutical Society of Great Britain
Profiel
David A.
Kennard is a Member of the Royal Pharmaceutical Society of Great Britain.
He was previously the Chief Executive Officer & Director of NeuroTargets Ltd.
and the Chief Operating Officer of Silence Therapeutics Plc.
He also served as the Director-European Operations at YM BioSciences, Inc. Kennard holds an MBA and a doctorate from the University of London.
Actieve functies van David A. Kennard
| Bedrijven | Functie | Begin |
|---|---|---|
Royal Pharmaceutical Society of Great Britain
 Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Corporate Officer/Principal | - |
Eerdere bekende functies van David A. Kennard
| Bedrijven | Functie | Einde |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Operationeel Directeur | - |
NeuroTargets Ltd.
 NeuroTargets Ltd. Pharmaceuticals: MajorHealth Technology NeuroTargets, Inc. develops novel therapeutic products. It discovers and develops new drugs for neurological diseases. The company develops products in the fields of diabetic neuropathy, pain resulting from nerve damage, spinal cord injuries and other trauma, and brain diseases associated with cognitive impairment such as stroke and Alzheimer's disease. NeuroTargets was founded in 1999 and is located at Guildford, UK. | President | - |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Opleiding van David A. Kennard
| University of London | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Bedrijven in privébezit | 3 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Royal Pharmaceutical Society of Great Britain
Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Commercial Services |
NeuroTargets Ltd.
NeuroTargets Ltd. Pharmaceuticals: MajorHealth Technology NeuroTargets, Inc. develops novel therapeutic products. It discovers and develops new drugs for neurological diseases. The company develops products in the fields of diabetic neuropathy, pain resulting from nerve damage, spinal cord injuries and other trauma, and brain diseases associated with cognitive impairment such as stroke and Alzheimer's disease. NeuroTargets was founded in 1999 and is located at Guildford, UK. | Health Technology |
